Birdwatch Note
2024-02-28 11:30:30 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Important context: The drug so far only worked in mice. https://www.livemint.com/science/health/tata-institute-comes-up-with-a-rs-100-drug-to-prevent-cancer-recurrence-doctors-to-start-human-trials-soon-11709098302960.html There are severe limitations in comparing mice to humans in cancer research: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902221/#:~:text=Although%20mice%20are%20most%20commonly,a%20cancer%20cure%20%5B13%5D. Therefore the human trials need to be conducted to prove effectiveness in humans.
Written by 0BE88BCD4AC1F0567051522B082EB1B55C80AF027D3095D97680AD3D7A0D21ED
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1762774794687361093
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1762802453722907063
- noteId - 1762802453722907063
- participantId -
- noteAuthorParticipantId - 0BE88BCD4AC1F0567051522B082EB1B55C80AF027D3095D97680AD3D7A0D21ED Participant Details
- createdAtMillis - 1709119830910
- tweetId - 1762774794687361093
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Important context: The drug so far only worked in mice. https://www.livemint.com/science/health/tata-institute-comes-up-with-a-rs-100-drug-to-prevent-cancer-recurrence-doctors-to-start-human-trials-soon-11709098302960.html There are severe limitations in comparing mice to humans in cancer research: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902221/#:~:text=Although%20mice%20are%20most%20commonly,a%20cancer%20cure%20%5B13%5D. Therefore the human trials need to be conducted to prove effectiveness in humans.
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-02-28 11:30:30 UTC (1709119830910) |
2024-02-28 15:04:21 UTC (1709132661562) |
CURRENTLY_RATED_HELPFUL | 2024-03-07 12:28:42 UTC (1709814522945) |
CURRENTLY_RATED_HELPFUL | 2024-02-28 15:04:21 UTC (1709132661562) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-03-02 08:29:39 -0600 | Rating Details | |
| 2024-02-28 18:51:07 -0600 | Rating Details | |
| 2024-02-28 12:11:44 -0600 | Rating Details | |
| 2024-02-28 11:37:51 -0600 | Rating Details | |
| 2024-02-28 09:15:16 -0600 | Rating Details | |
| 2024-02-28 08:59:41 -0600 | Rating Details | |
| 2024-02-28 08:56:54 -0600 | Rating Details | |
| 2024-02-28 08:56:40 -0600 | Rating Details | |
| 2024-02-28 07:48:07 -0600 | Rating Details | |
| 2024-02-28 07:40:46 -0600 | Rating Details | |
| 2024-02-28 07:16:34 -0600 | Rating Details | |
| 2024-02-28 06:59:00 -0600 | Rating Details | |
| 2024-02-28 06:55:08 -0600 | Rating Details | |
| 2024-02-28 06:43:53 -0600 | Rating Details | |
| 2024-02-28 06:43:27 -0600 | Rating Details | |
| 2024-02-28 06:28:20 -0600 | Rating Details | |
| 2024-02-28 06:24:04 -0600 | Rating Details | |
| 2024-02-28 06:21:36 -0600 | Rating Details | |
| 2024-02-28 06:15:35 -0600 | Rating Details | |
| 2024-02-28 06:13:29 -0600 | Rating Details | |
| 2024-02-28 06:05:37 -0600 | Rating Details | |
| 2024-02-28 06:00:11 -0600 | Rating Details | |
| 2024-02-28 05:58:51 -0600 | Rating Details | |
| 2024-02-28 05:41:33 -0600 | Rating Details | |
| 2024-02-29 07:52:59 -0600 | Rating Details | |
| 2024-02-28 19:08:40 -0600 | Rating Details | |
| 2024-02-28 17:21:27 -0600 | Rating Details | |
| 2024-02-28 17:13:34 -0600 | Rating Details | |
| 2024-02-28 12:14:04 -0600 | Rating Details | |
| 2024-02-28 10:04:47 -0600 | Rating Details | |
| 2024-02-28 08:11:47 -0600 | Rating Details | |
| 2024-02-28 07:57:23 -0600 | Rating Details | |
| 2024-02-28 07:00:59 -0600 | Rating Details | |
| 2024-02-28 06:58:18 -0600 | Rating Details | |
| 2024-02-28 06:47:45 -0600 | Rating Details | |
| 2024-02-28 06:23:55 -0600 | Rating Details | |
| 2024-02-28 06:14:53 -0600 | Rating Details | |
| 2024-02-28 06:04:35 -0600 | Rating Details | |
| 2024-02-28 05:53:59 -0600 | Rating Details | |
| 2024-02-28 05:46:03 -0600 | Rating Details | |
| 2024-02-28 05:38:46 -0600 | Rating Details | |
| 2024-03-02 14:05:06 -0600 | Rating Details | |
| 2024-03-01 03:33:57 -0600 | Rating Details | |
| 2024-02-28 11:11:56 -0600 | Rating Details | |
| 2024-02-28 09:01:07 -0600 | Rating Details | |
| 2024-02-28 07:34:05 -0600 | Rating Details | |
| 2024-02-28 07:25:37 -0600 | Rating Details | |
| 2024-02-28 06:38:05 -0600 | Rating Details | |
| 2024-02-28 06:06:10 -0600 | Rating Details | |
| 2024-02-28 06:05:04 -0600 | Rating Details | |
| 2024-02-28 06:04:29 -0600 | Rating Details | |
| 2024-02-28 06:00:55 -0600 | Rating Details | |
| 2024-02-28 05:40:00 -0600 | Rating Details | |
| 2024-02-28 05:37:59 -0600 | Rating Details |